摘要
目的:回顾总结我国近十年252锎中子治疗宫颈癌的现状。方法:通过中国期刊全文数据库,输入主题词"锎"和"宫颈癌",检索记录文献,汇总研究病例进行生存率分析。结果:可供分析的10篇报道,研究病例总数为553例,临床疗效评价,CR 522例(94.4%),PR 31例(5.6%),RR 553例(100.0%);1、2、3、5年的局控率和生存率分别为100.0%和98.4%、100.0%和93.7%、92.2%和85.0%及82.6%和79.2%;生存时间与临床分期密切相关。Ⅱ期、Ⅲ期和ⅣA期3年生存率分别为95.3%、75.0%和25.0%,5年生存率分别为89.2%、75.0%和30.0%,而对于已确定分期的患者,其2年和3年生存率,甚至5年生存率差异不显著。放射性直肠炎和膀胱炎(>2级)的发生率分别为12.1%和4.7%;远期并发症发生率为3.8%。结论:252锎中子治疗宫颈癌存活率高,并发症发生率低,具有较好的临床应用价值。
Objective：To analyze the current statement of californium-252 neutron brachytherapy on cervical cancer in China by reviewing the published papers. Methods：The published clinical studies in China were searched in Chinese Journal Fulhext Database（ CJFD）, and the overall survival rate was analyzed in the collected cases. Results：Ten eligible studies were combined and used in the present analysis. In total 553 cases, 522 cases achieved CR（94.4% ）, 31 cases PR（5.6% ）, so the RR（ reactive rate） was 100. 0% （553/553）. The overall local control rate and survival rate of 1-, 2-, 3-, 5-year were 100. 0% , 98.4% ; 100. 0% , 93.7% ; 92. 2%, 85.0% and 82. 6% , 79.2%. The 3-year overall survival rate of stage Ⅱ , stageⅢ and stageⅣa were 95.3% , 75.0% and 25.0% , and their 5-year overall survival rate were 89. 2% , 75.0% and 30. 0% , which confirmed fatherly that the clinical staging was associated with the prognosis in cervical cancer. However, it noted that there were no significantly differences among 2-year, 3-year and 5-year survival rate in a defined staging. The complication rate was 12. 1% for proctitis, 4. 7% for cystitis ; meanwhile the morbid- ity of late complications was 3.8%. Conclusion： Californium-252 neutron brachytherapy is a challenging approach to cure cervical cancer with higher survival rate and fewer complications.
出处
《临床肿瘤学杂志》
CAS
2009年第9期803-807,共5页
Chinese Clinical Oncology
基金
重庆市自然科学基金资助项目(2004BB5246)
关键词
宫颈癌
252锎
放射治疗
Cervical cancer
Californium-252 neutron
Radiotherapy
